[Investigation of the effects of low dose aspirin therapy on primary and secondary prevention of cardiovascular disease].
We examined the efficacy of low-dose aspirin for the primary prevention of atherosclerotic events in patients with type 2 diabetes. Multicenter, prospective, randomized, open -label, blinded end-point trial enrolled 2,539 patients with type 2 diabetes. A total of 154 atherosclerotic events occurred: 68 in the aspirin group and 86 in the nonaspirin group (log -rank test, p = 0.16). The multicenter study was performed to find out whether aspirin or trapidil would improve clinical outcome. The study was a multicenter, open-label, randomized controlled trial of aspirin 81 mg/day, trapidil 300 mg/day, and no antiplatelets in patients with acute myocardial infarction (AMI) admitted within 1 month from the onset of symptoms. Long-term use of aspirin reduced the incidence of recurrent AMI (p = 0.0045).
Soejima
Hirofumi
H
Health Care Center, Kumamoto University.
Ogawa
Hisao
H
D001241:Aspirin / Q000008:administration & dosage*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D003925:Diabetic Angiopathies / Q000517:prevention & control*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011446:Prospective Studies; D014192:Trapidil / Q000627:therapeutic use
D010975:Platelet Aggregation Inhibitors; D014192:Trapidil; D001241:Aspirin